Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1CNS 1

Conditions

Glioblastoma 4Small Cell Lung Carcinoma 2Breast Neoplasms 2Pancreatic Neoplasms 1Pancreatic Cancer Metastatic 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lung Neoplasms 1Gliosarcoma 1Glioma 1Chondrosarcoma 1Cholangiocarcinoma 1Carcinoma, Intraductal, Noninfiltrating 1Brain Neoplasms 1Arthritis, Rheumatoid 1

Interventions

Gemcitabine 111Cisplatin 75Oxaliplatin 43pembrolizumab 34Fluorouracil 31Capecitabine 30durvalumab 26Leucovorin 25lenvatinib 23Magnetic Resonance Spectroscopy 14Irinotecan 13Nivolumab 12Albumin-Bound Paclitaxel 12Specimen Handling 11Radiofrequency Ablation 11Drug Therapy 11Biopsy 11tislelizumab 10pemigatinib 10apatinib 10Taxes 10Floxuridine 10130-nm albumin-bound paclitaxel 10Radiotherapy 9Bevacizumab 9Folfox protocol 8Carboplatin 8tremelimumab 7atezolizumab 7S 1 (combination) 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Cholangiocarcinoma × Chloroquine × Clear all
NCT02496741 2020-01-09

MACIST

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Phase 1/2 Completed
15 enrolled
CNSGastrointestinalSarcoma

Chondrosarcoma, Glioma, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡